EPO906 [patupilone] therapy in patients with metastatic carcinoid tumors and other neuroendocrine tumors
Phase of Trial: Phase II
Latest Information Update: 03 Mar 2017
At a glance
- Drugs Patupilone (Primary)
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- 07 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Oct 2012 Planned number of patients changed from 48 to 32.
- 17 Oct 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.